Treatment of adipocytes
The present disclosure provides compositions comprising a lyn kinase activator and TRPM8 agonist, and to methods of: reducing blood glucose levels, weight gain, or fat depot levels; treating metabolic syndrome, Syndrome X, obesity, prediabetes, type II diabetes, type I diabetes; treating hypercholesterolemia, hypertension, coronary heart disease, diabetic neuropathy, lipodystrophy, diabetic retinopathy, erectile dysfunction, kidney disease, dyslipidemia, dyslipoproteinemia, a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, or pancreatitis; inducing the beiging of adipocytes; and preventing pancreatic beta cell degeneration.
1. A composition comprising:
a lyn kinase activator, or a pharmaceutically acceptable salt thereof; and
a TRPM8 agonist; wherein the lyn kinase activator is of the formula:
or a pharmaceutically acceptable salt thereof, and the TRPM8 agonist is menthol.
2. A method of treating obesity, prediabetes, type II diabetes, type I diabetes, or dyslipidemia, in a mammal in need thereof, comprising administering to the mammal an effective amount of a lyn kinase activator having the formula:
or a pharmaceutically acceptable salt thereof, and menthol.
3. The method of claim 2 , wherein the lyn kinase activator and menthol are present in the same composition.
4. A method of inducing the beiging of adipocytes in a mammal in need thereof, comprising administering to the mammal an effective amount of a lyn kinase activator having the formula:
or a pharmaceutically acceptable salt thereof, and menthol.
5. The method of claim 4 , wherein the lyn kinase activator and menthol are present in the same composition.